Zymeworks INC. (ZYME) — SEC Filings

Overview

Zymeworks INC. (ZYME) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 1, 2026: On April 1, 2026, Zymeworks Inc. filed an 8-K report detailing the departure of certain officers and directors, as well as compensatory arrangements. The filing also includes financial statements and exhibits related to these changes.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Zymeworks INC. is neutral.

Filing Type Overview

Zymeworks INC. (ZYME) has filed 26 8-K, 2 DEF 14A, 6 10-Q, 2 10-K, 6 SC 13G/A, 2 SC 13G, 1 SC 13D with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• Zymeworks Inc. Files 8-K: Officer/Director Changes & Compensation — 8-K · Apr 1, 2026 Risk: medium
  On April 1, 2026, Zymeworks Inc. filed an 8-K report detailing the departure of certain officers and directors, as well as compensatory arrangements. The filing
• 8-K Filing — 8-K · Dec 30, 2025
• Zymeworks Inc. Announces Corporate Changes and Filings — 8-K · Nov 18, 2025 Risk: medium
  Zymeworks Inc. announced on November 16, 2025, a series of significant corporate events. These include the departure of directors, the election of new directors
• Zymeworks Inc. Files 8-K Report — 8-K · Nov 17, 2025 Risk: low
  On November 17, 2025, Zymeworks Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific materia
• Zymeworks Sets Dec. 30 Virtual Shareholder Meeting; Board Backs All Proposals — DEF 14A · Nov 10, 2025 Risk: low
  Zymeworks Inc. (ZYME) is holding its Annual Meeting of Stockholders on December 30, 2025, at 9:00 a.m. Pacific Time, virtually via live audio webcast. Stockhold
• Zymeworks Narrows Losses by 60% on Soaring Collaboration Revenue — 10-Q · Nov 6, 2025 Risk: medium
  Zymeworks Inc. reported a significant increase in revenue from research and development collaborations, reaching $103.45 million for the nine months ended Septe
• Zymeworks Inc. Files 8-K Report — 8-K · Sep 2, 2025 Risk: low
  On September 2, 2025, Zymeworks Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure
• Zymeworks Inc. Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Aug 11, 2025 Risk: medium
  On August 9, 2025, Zymeworks Inc. filed an 8-K report detailing several key events. These include the entry into a material definitive agreement, unregistered s
• Zymeworks' Q2 Loss Widens Amid Rising R&D, Revenue Dip — 10-Q · Aug 7, 2025 Risk: high
  Zymeworks Inc. reported a net loss of $38.4 million for the three months ended June 30, 2025, a significant increase from the $29.7 million net loss in the same
• Zymeworks Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Jun 27, 2025 Risk: medium
  On June 26, 2025, Zymeworks Inc. filed an 8-K report detailing an entry into a material definitive agreement. The filing also covers unregistered sales of equit
• Zymeworks Inc. Files 8-K with Financials and Other Events — 8-K · May 30, 2025 Risk: low
  Zymeworks Inc. filed an 8-K on May 30, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as well
• Zymeworks Inc. Files Q1 2025 10-Q Report — 10-Q · May 8, 2025 Risk: medium
  Zymeworks Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational activities during the fi
• Zymeworks Inc. Files 2024 10-K — 10-K · Mar 5, 2025 Risk: medium
  Zymeworks Inc. filed its 2024 10-K on March 5, 2025, reporting its fiscal year ending December 31, 2024. The company, previously known as Zymeworks Delaware Inc
• Zymeworks Inc. Announces Board and Officer Changes — 8-K · Feb 18, 2025 Risk: medium
  Zymeworks Inc. announced on February 17, 2025, a change in its board of directors and executive officers. The filing details the departure of certain directors
• Zymeworks Inc. Files 8-K on Operations and Financials — 8-K · Jan 8, 2025 Risk: low
  Zymeworks Inc. filed an 8-K on January 8, 2025, reporting on its results of operations, other events, and financial statements. The filing details the company's
• Zymeworks Inc. Shareholder Meeting Results Announced — 8-K · Dec 11, 2024 Risk: low
  On December 10, 2024, Zymeworks Inc. announced the results of its annual general meeting of shareholders. Shareholders voted to elect the nominated directors, a
• Zymeworks Inc. Files 8-K Report — 8-K · Nov 21, 2024 Risk: low
  On November 21, 2024, Zymeworks Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulat
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 13, 2024
• Zymeworks Inc. Files Q3 2024 10-Q — 10-Q · Oct 31, 2024 Risk: medium
  Zymeworks Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter of 2024, detailing its cash
• Zymeworks Files 2024 Proxy Statement — DEF 14A · Oct 29, 2024 Risk: low
  Zymeworks Inc. filed its definitive proxy statement (DEF 14A) on October 29, 2024, for its annual meeting scheduled for December 10, 2024. The filing outlines t
• Zymeworks Inc. Announces Board Changes — 8-K · Oct 18, 2024 Risk: low
  On October 15, 2024, Zymeworks Inc. reported the departure of Director Dr. Paul Hastings and the appointment of Dr. Steven M. Altschuler as a new director. The
• Zymeworks Inc. Appoints New Directors, Adjusts Executive Compensation — 8-K · Sep 3, 2024 Risk: medium
  Zymeworks Inc. announced on August 30, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors,
• Zymeworks Inc. Files Material Definitive Agreement 8-K — 8-K · Aug 2, 2024 Risk: medium
  On August 2, 2024, Zymeworks Inc. filed an 8-K report detailing a material definitive agreement. The filing does not provide specific details about the agreemen
• Zymeworks Inc. Files 8-K Report — 8-K · Aug 1, 2024 Risk: low
  On August 1, 2024, Zymeworks Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation
• Zymeworks Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 1, 2024 Risk: medium
  Zymeworks Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter of 20
• Zymeworks Inc. Announces Director Changes and Officer Compensation Details — 8-K · Jul 25, 2024 Risk: medium
  On July 19, 2024, Zymeworks Inc. filed an 8-K report detailing the departure of Director Dr. Paul Hastings and the appointment of Dr. Steven A. Rosenberg as a n
• Zymeworks Inc. Files 8-K Report — 8-K · Jun 10, 2024 Risk: low
  On June 10, 2024, Zymeworks Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." Specific details rega
• Zymeworks Appoints New Chief Medical Officer — 8-K · May 3, 2024 Risk: medium
  On May 3, 2024, Zymeworks Inc. filed an 8-K report detailing the appointment of Dr. Paul W. Smith as Chief Medical Officer, effective May 6, 2024. Dr. Smith bri
• Zymeworks Inc. Files 10-Q for Q1 2024 — 10-Q · May 2, 2024 Risk: low
  Zymeworks Inc. (ZYME) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Zymeworks Inc. filed its 10-Q report for the period ending March 31, 2024. Th
• Zymeworks Inc. Files 8-K: Board & Officer Changes — 8-K · Apr 4, 2024 Risk: medium
  On April 3, 2024, Zymeworks Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on the
• Zymeworks Inc. Reports Board and Executive Compensation Changes — 8-K · Apr 1, 2024 Risk: medium
  On March 31, 2024, Zymeworks Inc. reported changes in its board of directors and executive compensation arrangements. The filing details the departure of certai
• Zymeworks Inc. Announces Director Changes and Officer Compensation — 8-K · Mar 28, 2024 Risk: low
  On March 27, 2024, Zymeworks Inc. filed an 8-K report detailing the departure of Director Dr. Paul Hastings and the appointment of Dr. Steven A. Rosenberg as a
• Zymeworks Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 6, 2024 Risk: low
  Zymeworks Inc. (ZYME) filed a Annual Report (10-K) with the SEC on March 6, 2024. Zymeworks Inc. filed its 2023 Form 10-K on March 6, 2024, reporting on the fis
• Zymeworks Reports Executive/Board Changes and Compensation Arrangements — 8-K · Feb 22, 2024 Risk: medium
  Zymeworks Inc. filed an 8-K on February 22, 2024, to report an event related to the departure or election of directors or officers, and compensatory arrangement
• EcoR1 Capital Discloses Zymeworks Stake in New 13D Filing — SC 13D · Feb 22, 2024 Risk: medium
  EcoR1 Capital, LLC filed an SC 13D on February 22, 2024, regarding its ownership in Zymeworks Inc. The filing indicates EcoR1 Capital, LLC, a Delaware-incorpora
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Morgan Stanley Amends Zymeworks Stake on 12/31/23 — SC 13G/A · Feb 9, 2024 Risk: low
  Morgan Stanley filed an amended Schedule 13G/A on February 9, 2024, indicating its ownership of Zymeworks Inc. common stock as of December 31, 2023. This filing
• Zymeworks Reports Executive/Director Changes on Feb 6 — 8-K · Feb 8, 2024 Risk: medium
  Zymeworks Inc. filed an 8-K on February 8, 2024, reporting an event that occurred on February 6, 2024. This filing indicates a change in the company's executive
• BlackRock Discloses 6.0% Stake in Zymeworks Inc. — SC 13G · Jan 29, 2024
  BlackRock Inc., a massive investment firm, reported on January 29, 2024, that it holds a significant stake in Zymeworks Inc. (ZWE), a pharmaceutical company. As
• Zymeworks 8-K: Executive/Director Changes or Compensation Update — 8-K · Jan 5, 2024
  Zymeworks Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 3, 2024. This filing indicates a change in the company's executive o
• Zymeworks Files 8-K on Operations & Financial Condition — 8-K · Jan 4, 2024
  Zymeworks Inc. filed an 8-K on January 4, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that

Risk Profile

Risk Assessment: Of ZYME's 35 recent filings, 1 were flagged as high-risk, 19 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Zymeworks INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $103.45M
• Net Income: -$39.92M
• EPS: N/A
• Debt-to-Equity: 0.24
• Cash Position: $64.83M
• Operating Margin: N/A
• Total Assets: $397.27M
• Total Debt: $77.21M

Key Executives

• Kenneth Galbraith
• Dr. Paul Hastings
• Dr. Steven M. Altschuler
• Ms. Neda Jafari
• Dr. Paul J. Hastings
• Ms. Jennifer L. D. Good
• Dr. Neil Gallagher
• Dr. Steven A. Rosenberg
• Dr. Paul W. Smith
• Anthony J. Caldwell, Esq.

Industry Context

Zymeworks operates in the biotechnology sector, focusing on the development of bispecific antibodies for the treatment of cancer. This industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. The competitive landscape includes numerous companies vying for breakthroughs in oncology, with a strong emphasis on innovative therapeutic modalities.

Top Tags

financials (6) · corporate-governance (5) · filing (4) · 8-K (4) · SEC Filing (4) · Biotechnology (4) · 10-Q (4) · pharmaceuticals (4) · governance (4) · compensation (3)

Key Numbers

• CIK Number: 0001937653 — Identifies Zymeworks Inc. in SEC filings.
• Accession Number: 0001193125-26-135610 — Unique identifier for this specific SEC filing.
• Filing Date: 2026-04-01 — Date Zymeworks Inc. submitted this report.
• Annual Meeting Date: 2025-12-30 — Date of Zymeworks Inc.'s virtual Annual Meeting of Stockholders
• Record Date: 2025-11-03 — Date for determining stockholders entitled to vote at the Annual Meeting
• Common Stock Shares Outstanding: 74,835,565 — Number of common stock shares held by 78 registered stockholders as of the Record Date
• Exchangeable Shares Outstanding: 553,184 — Number of exchangeable shares held by six registered holders eligible to vote as of the Record Date
• Proxy Solicitation Fees: C$79,860 — Amount Zymeworks will pay Kingsdale Advisors for proxy solicitation services
• Class I Directors: 3 — Number of Class I directors nominated for election to hold office until the 2028 annual meeting
• Quorum Requirement: 33 1/3% — Percentage of voting power required for a quorum at the Annual Meeting
• Proxy Card Deadline: 2025-12-29 — Deadline for mailing proxy cards for stockholders (11:59 p.m. Eastern Time)
• Exchangeable Share Voting Deadline: 2025-12-24 — Deadline for mailing voting instruction cards for registered holders of exchangeable shares (2:00 p.m. Eastern Time)
• Notice of Internet Availability Sent: 2025-11-18 — Approximate date the Notice of Internet Availability of Proxy Materials is first being sent to stockholders
• Research and development collaborations revenue: $103.45M — Increased from $45.27M in 2024 for the nine months ended September 30, 2025, a 128.5% increase.
• Net loss for nine months: $39.92M — Decreased from $99.19M in 2024, a 59.7% improvement.

Forward-Looking Statements

• {"claim":"Zymeworks Inc. will release further details regarding the specific executive or director changes.","entity":"Zymeworks Inc.","targetDate":"Q1 2024","confidence":"high"}
• {"claim":"The market will react to the specific details of the leadership changes once they are disclosed.","entity":"ZYME stock price","targetDate":"Q1 2024","confidence":"medium"}

Frequently Asked Questions